Your session is about to expire
← Back to Search
Sunitinib for Thymoma
Study Summary
This trial is testing the safety and effectiveness of sunitinib as a treatment for advanced thymus cancer. Eligible participants must be at least 18 years old and have had at least one previous chemotherapy treatment containing platinum. Sunitinib will be taken once daily for 4 weeks, followed by 2 weeks of rest. This 6-week period will be repeated as long as the tumor does not continue to grow and there are no severe side effects.
- Thymoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 305 Patients • NCT01984242Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your hemoglobin levels should be at least 9 grams per deciliter (g/dL) or higher.You have a measurable tumor that can be evaluated using a specific set of criteria called RECIST 1.1.Your white blood cell count is at least 3,000 per microliter.You are currently participating in another study for an experimental treatment.You must have a confirmed diagnosis of thymoma or thymic carcinoma from a qualified pathology department.You need to be physically able to take care of yourself and do your normal daily activities without help most of the time.You are expected to live for at least three more months.You are expected to live for at least three more months.You have cancer that has spread to your brain and is causing symptoms.You must be 18 years old or older to participate.You cannot have had chemotherapy, radiation therapy, or a major surgery within the 4 weeks before starting the trial.Your body has a minimum amount of infection-fighting white blood cells called neutrophils.You had cancer that required treatment within the past 5 years, except for non-melanoma skin cancer, thyroid papillary carcinoma or early-stage cervical cancer that was treated successfully.You have already received chemotherapy treatment or have chosen not to receive it. Your cancer has continued to progress despite this treatment.Your cancer is treatable with potentially curative therapy.
- Group 1: Group 2 (Thymic carcinoma only)
- Group 2: Group 1 (Thymoma and thymic carcinoma)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this trial open to new participants?
"This medical trial is currently not enrolling any patients. Initially posted on May 15th 2012, and last updated on May 17th 2022, this study is currently inactive. Nevertheless, there are 36 studies actively recruiting cancer of thymus sufferers and a further 34 trials for Sunitinib accepting participants at the moment."
How many individuals have opted-in to participate in this clinical trial?
"Unfortunately, this research trial is not presently accepting new applicants. Initially posted on the 15th of May 2012 and last amended on 17th of May 2022, this clinical investigation has been paused for now. However, those in search of alternate studies can consider 36 trials that are admitting patients with thymus cancer or 34 studies recruiting Sunitinib participants."
Have there been past investigations involving Sunitinib?
"At this moment in time, 11 clinical trials are underway at Phase 3 for Sunitinib. Most of the tests take place near Hannover, Niedersachsen; however, 3860 sites host trialling for Sunitinib around the world."
Might I be eligible to join this research endeavor?
"This medical trial is seeking 56 patients who have malignant thymus cancer, aged 18 to 100. Those wishing to participate must satisfy the following criteria: leukocytes greater than or equal to 3,000/mcL); prior cytotoxic chemotherapy; measurable disease according to RECIST 1.1; histological confirmation of malignancy by an accredited pathology department; no recent major surgery or radiation therapy; age over 18 years old with a life expectancy exceeding three months, hemoglobin levels higher than 9 g/dL and absolute neutrophil count above 1,200/mcL as well as ECOG performance status lower or equal"
How is Sunitinib generally employed to help patients?
"Sunitinib is a potent therapeutic option for soft tissue sarcoma (STS), gastrointestinal stromal tumors, and metastatic pancreatic neuroendocrine tumors."
Is this investigation open to people of advanced age?
"According to the criteria, individuals aged between 18 and 100 years can apply for this clinical trial. Additionally, there are 6 trials designed specifically for minors and 69 that cater to elderly patients."
Has Sunitinib received the endorsement of the Food and Drug Administration?
"Our team at Power has given Sunitinib a safety score of 2, as there is some existing data in support of its security but none for efficacy."
Share this study with friends
Copy Link
Messenger